{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-113820","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.626648+00:00","generated_at":"2026-05-22T11:41:27.496507+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially","bullets":["Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).","Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.","Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.","Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.","FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-113820","json":"https://secwatch.observer/filing/0001193125-25-113820.json","markdown":"https://secwatch.observer/filing/0001193125-25-113820.md","text":"https://secwatch.observer/filing/0001193125-25-113820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/0001193125-25-113820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/d821404d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:41:27.496507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}